Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)

SHA:600993 Revenue

Mayinglong Pharmaceutical Group had revenue of 949.25M CNY in the quarter ending September 30, 2026, with 6.87% growth. This brings the company's total for the last twelve months to 3.99B, up 5.75% year-over-year. In the year 2025, Mayinglong Pharmaceutical Group had annual revenue of 3.87B with 3.72% growth. That makes Mayinglong Pharmaceutical Group the 10,261st largest company in the world by revenue and 1,671st in China.

• Revenue (ttm): 3.99B
• Revenue Growth: +5.75%
• P/S Ratio: 2.71
• Revenue / Employee: 1.57M
• Employees: 2,544
• Market Cap: 10.80B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Industry Division 2.40B 59.9%
• Pharmaceutical Business Segment 1.17B 29.1%
• Medical Services Division 421.83M 10.5%
• Undistributed Amount 22.48M 0.6%

By Geography

Chart

• Mainland China 3.86B 99.9%
• outside Mainland China 4.04M 0.1%

Fiscal year ended Dec 31, 2025 See the full SHA:600993 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.87B	138.58M	3.72%
Dec 31, 2024	3.73B	591.28M	18.85%
Dec 31, 2023	3.14B	-395.63M	-11.20%
Dec 31, 2022	3.53B	147.32M	4.35%
Dec 31, 2021	3.39B	593.47M	21.26%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error